Biotech Esperion Therapeutics News Portfolio

FDA Approves Esperion’s Cholesterol-Lowering Drug Nexletol

Biotech News | 25.02.2020

The US Food and Drug Administration approves Esperion’s oral LDL-Cholesterol (LDL-C) lowering...

Biotech Esperion Therapeutics News

Esperion Therapeutics: Important Days Ahead!

Biotech News | 18.02.2020

The next two weeks are of critical importance for the US pharmaceutical company Esperion...

Biotech Esperion Therapeutics News Portfolio

Esperion Therapeutics to Present Pooled Analyses from its Phase 3 Trials with Bempedoic Acid at AHA Congress

Biotech News | 04.11.2019

Esperion Therapeutics today announced that it will present a pooled analysis of its 4 phase 3...

Biotech Esperion Therapeutics News Portfolio

Esperion’s Cholesterol-Lowering Drug Bembedoic Acid With Positive Top-Line Results from Phase 2 Trial in Patients with Type 2 Diabetes

Biotech News | 29.08.2019

Esperion Therapeutics, a US-based pharmaceutical company specialized in the development of oral...